Comparison of dexmedetomidine with midazolam for third molar surgery: A meta-analysis of randomized controlled trials.

INTRODUCTION: The analgesic sedation of dexmedetomidine compared with midazolam for third molar surgery remains controversial. We conduct a systematic review and meta-analysis to explore the influence of dexmedetomidine versus midazolam for third molar surgery. METHODS: We have searched PubMed, EMbase, Web of science, EBSCO, and Cochrane library databases through December 2022 for randomized controlled trials assessing the effect of dexmedetomidine versus midazolam for third molar surgery. This meta-analysis was performed using the random-effect model. RESULTS: Four randomized controlled trials were included in the meta-analysis. Overall, compared with midazolam for third molar surgery, dexmedetomidine administration leads to comparable oxygen saturation (standard mean difference [SMD] = 0.25; 95% confidence interval [CI] = -0.24 to 0.74; P = .31), heart rate (SMD = -0.37; 95% CI = -1.18 to 0.44; P = .37), SBP (SMD = -0.24; 95% CI = -0.57 to 0.09; P = .16), DBP (SMD = -0.26; 95% CI = -0.60 to 0.07; P = .12), as well as nausea and vomiting (OR = 0.58; 95% CI = 0.05-6.61; P = .66). CONCLUSIONS: Dexmedetomidine may obtain the comparable sedation efficacy with midazolam for third molar surgery.

Adsorption of Ni2+ in aqueous solution by KMnO4 modified biomass: investigation on adsorption kinetics and modification mechanism.

In this study, KMnO4 modification was proved to effectively increase the Ni2+ adsorption capacity of biomass. In order to clarify the KMnO4 modification mechanism, the Ni2+ adsorption characteristics of KMnO4 modified corncob (PPCB) under adsorption time, pH and Ni2+ concentration were studied. The results showed that the adsorption was the pseudo second-order kinetic process, indicating that chemisorption was the dominated process, which followed the Langmuir isotherm model and the highest Ni2+ adsorption capacity of PPCB reached 35.6 mg/g. By KMnO4 modification, the corncob was oxidized to generate carboxylates, and the MnO2 (reduction product) was loaded on the modified corncob, both carboxylates and MnO2 increased the Ni2+ adsorption capacity of PPCB. The molecular dynamic results indicated the carboxylate structures had the strongest adsorption capacity. Moreover, the Ni2+ removal efficiency of KMnO4 modified biomass decreased linearly with the increase of lignin content in biomass, while KMnO4 modified lignin showed a good adsorption performance, indicating that the cross-linked structures between lignin and other components in the biomass could inhibit the adsorption capacity of PPCB.

Biodegradable poly(D, L-lactide-co-glycolide) (PLGA) microspheres for sustained release of risperidone: Zero-order release formulation.

The preparation and investigation of sustained-release risperidone-encapsulated microspheres using erodible poly(D, L-lactide-co-glycolide) (PLGA) of lower molecular weight were performed and compared to that of commercial Risperdal Consta™ for the treatment of schizophrenia. The research included screening and optimizing of suitable commercial polymers of lower molecular weight PLGA50/50 or the blends of these PLGA polymers to prepare microspheres with zero-order release kinetics properties. Solvent evaporation method was applied here while studies of the risperidone loaded microsphere were carried out on its drug encapsulation capacity, morphology, particle size, as well as in vitro release profiles. Results showed that microspheres prepared using 50504A PLGA or blends of 5050-type PLGAs exerted spherical and smooth morphology, with a higher encapsulation efficiency and nearly zero-order release kinetics. These optimized microspheres showed great potential for a better depot preparation than the marketed Risperdal Consta™, which could further improve the patient compliance.